{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:52:13Z","timestamp":1762674733777,"version":"3.41.2"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To observe the vascular development results of tertiary anti-vascular endothelial growth factor (anti-VEGF) therapy following spontaneous second reactivation of retinopathy of prematurity (ROP).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study included 22 infants (42 eyes) with Type 1 or aggressive ROP (A-ROP) who received three anti-VEGF drug treatments for ROP from January 2018 to December 2022. The vascular growth, possible associated risk factors, and the retinal vascularization (DB\/DF ratio) were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean follow-up was 17.6\u2009months. After the 3<jats:sup>rd<\/jats:sup> intravitreal injection, seven eyes showed complete vascularization (Group 1), while the remaining 35 eyes demonstrated persistent avascular retina (PAR) (Group 2). In Group 2, 17 eyes maintained a stable state and were classified in the regression subgroup. The other 18 eyes developed a 3<jats:sup>rd<\/jats:sup> reactivation (reactivation subgroup) and were treated with laser photocoagulation (LPC).<\/jats:p><jats:p>Birth weight (BW) was significantly lower in Group 2 than in Group 1 (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). The decision tree analysis shows that only infants weighing more than 1,250\u2009g (17.50%) had a chance to achieve complete retinal vascularization. The possibility of PAR was higher in patients with BW &amp;lt;1,250\u2009g than \u22651,250\u2009g (70.00% vs. 12.50%). In addition, most infants with BW\u2009\u2265\u20091,290\u2009g and initial ROP disease in Zone I or posterior Zone II developed PAR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Tertiary IVR can successfully treat a second ROP reactivation and improve peripheral retinal vascularization. BW is the most significant factor related to complete retinal vascularization. Our decision tree model may be helpful in predicting the prognosis of anti-VEGF drugs in the event of a second ROP reactivation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1421894","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T04:56:17Z","timestamp":1721364977000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Vascular development analysis: a study for tertiary anti-vascular endothelial growth factor therapy after second reactivation of retinopathy of prematurity"],"prefix":"10.3389","volume":"11","author":[{"given":"Xuerui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria Y.","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haodong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiquan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010","volume":"74","author":"Blencowe","year":"2013","journal-title":"Pediatr Res"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF02482615","article-title":"Results of U.S. randomized clinical trial of cryotherapy for ROP (CRYO-ROP)","volume":"74","author":"Palmer","year":"1990","journal-title":"Doc Ophthalmol"},{"key":"ref3","first-page":"233","article-title":"Early treatment for retinopathy of prematurity cooperative group. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.ophtha.2017.03.018","article-title":"Ranibizumab injection as primary treatment in patients with retinopathy of prematurity","volume":"124","author":"Huang","year":"2017","journal-title":"Ophthalmology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ophtha.2016.10.032","article-title":"Efficacy of primary intravitreal Ranibizumab for retinopathy of prematurity in China","volume":"124","author":"Feng","year":"2017","journal-title":"Ophthalmology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1111\/aos.14852","article-title":"Ranibizumab in retinopathy of prematurity - one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study","volume":"100","author":"Stahl","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ajo.2018.09.039","article-title":"A Spectrum of regression following intravitreal bevacizumab in retinopathy of prematurity","volume":"198","author":"Chen","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s00417-021-05499-0","article-title":"Long-term retinal vasculature abnormalities following intravitreal bevacizumab for retinopathy of prematurity","volume":"260","author":"Sternfeld","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1167\/iovs.16-20680","article-title":"Recurrence of retinopathy of prematurity after intravitreal Ranibizumab monotherapy: timing and risk factors","volume":"58","author":"Lyu","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","article-title":"Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti\u2013vascular endothelial growth factor monotherapy","volume":"40","author":"Ling","year":"2020","journal-title":"Retina"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"Wong","year":"2015","journal-title":"Retina"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e1004","DOI":"10.1111\/aos.14460","article-title":"Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity","volume":"98","author":"Cheng","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1136\/bjophthalmol-2018-312272","article-title":"Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: efficacy, anatomical outcomes and safety","volume":"103","author":"Kang","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00417-020-04605-y","article-title":"A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series","volume":"258","author":"Mart\u00ednez-Castellanos","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1007\/s00417-022-05628-3","article-title":"Repeated intravitreal ranibizumab for reactivated retinopathy of prematurity after intravitreal ranibizumab monotherapy: vascular development analysis","volume":"260","author":"Xia","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/IAE.0000000000001126","article-title":"Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study","volume":"37","author":"Lorenz","year":"2017","journal-title":"Retina"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1007\/s10792-018-01064-7","article-title":"Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression","volume":"39","author":"Vural","year":"2019","journal-title":"Int Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity, third edition","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12886-018-0685-6","article-title":"Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP)","volume":"18","author":"Li","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","article-title":"Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity","volume":"98","author":"Tahija","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1111\/j.1651-2227.2011.02445.x","article-title":"On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment \u2013 a review","volume":"100","author":"H\u00e5rd","year":"2011","journal-title":"Acta Paediatr"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.oret.2020.02.001","article-title":"Reactivation of retinopathy of prematurity in adults and adolescents","volume":"4","author":"Uner","year":"2020","journal-title":"Ophthalmology Retina"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"101018","DOI":"10.1016\/j.preteyeres.2021.101018","article-title":"Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF)","volume":"88","author":"Tsai","year":"2021","journal-title":"Prog Retin Eye Res"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1421894\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T04:56:19Z","timestamp":1721364979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1421894\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,19]]},"references-count":27,"alternative-id":["10.3389\/fmed.2024.1421894"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1421894","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2024,7,19]]},"article-number":"1421894"}}